Thieu Nguyen, MD
Cardiology · Houston, TXNPI 1609967165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,478 of the $5,413 with a category attached, or 64.2%. 17 manufacturers reported payments, led by Boston Scientific at 47.2% of the total. Reporting peaked in 2023 at $2,817 and has fallen 89.7% since, to $291 in 2025.
Across 102 payments — averaging $53.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Johnson & Johnson$945
- E.r. Squibb & Sons, L.L.C.$382
- Abbott$299
- AstraZeneca$269
- Abiomed$149
- plus $816 from 11 others
What the payments were for
- Travel & lodging$1,93536%
- Food & beverage$3,47864%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $2,553 |
| Johnson & Johnson | 34 | $945 |
| E.r. Squibb & Sons, L.L.C. | 14 | $382 |
| Abbott | 11 | $299 |
| AstraZeneca | 4 | $269 |
| Abiomed | 1 | $149 |
| Gilead | 1 | $125 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| GSK | 1 | $124 |
| Pfizer | 6 | $119 |
| Dexcom, Inc. | 1 | $117 |
| Amgen | 4 | $85 |
| Bayer | 1 | $31 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Novartis | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$2,111
- XARELTO$341
- FARXIGA$250
- Impella$149
- Vemlidy$125
- ZENPEP$125
- AREXVY$124
- FREESTYLE LIBRE 3$118
- DEXCOM G7 GSS (161)$117
How this compares
$5,413 in reported general payments places this provider in the 80th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $242,207 |
| XareltoRivaroxaban | 182 | $201,812 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 1,063 | $152,905 |
| Desonide | 707 | $114,439 |
| VascepaIcosapent Ethyl | 118 | $88,664 |
| Ranolazine ErRanolazine | 305 | $52,786 |
| FarxigaDapagliflozin Propanediol | 31 | $46,153 |
| EntrestoSacubitril/Valsartan | 38 | $38,631 |
| Amiodarone Hcl | 90 | $9,425 |
| Icosapent Ethyl | 26 | $8,716 |
| Metoprolol Succinate | 343 | $3,612 |
| Flecainide Acetate | 47 | $2,339 |
| Omega-3 Acid Ethyl Esters | 27 | $1,034 |
| ClopidogrelClopidogrel Bisulfate | 124 | $1,030 |
| Atorvastatin Calcium | 138 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $242,207195 claims |
| Johnson & JohnsonXarelto | $945 | $201,812182 claims |
| AstraZenecaFarxiga | $269 | $46,15331 claims |
| NovartisEntresto | $24 | $38,63138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 cardiology providers in Texas.
Other cardiology in Houston
- Sheikh AhmedHouston$14K
- Ramon TyHouston$11K
- Nadim ZaccaHouston$2K
- Julian KangHouston$0
- Leroy SterlingHouston$0
- Harvey SluskyWebster$26K
- Shiny MathewkuttyDallas$24K
- Lane MillerCollege Station$11K
- Faizan IftikharMcKinney$7K
- Nadir AliWebster$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.